Eli Lilly has now submitted a new drug application (NDA) for GLP-1RA orforglipron to the FDA for use in adults with obesity.

Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.

The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.

Anova Enterprises has launched the AnovaOS SaaS platform, a new AI-based patient matching solution for clinical trials.

FL is the most common indolent form of B-cell NHL. Credit: Motortion Films/Shutterstock.com. At the American Society of Hematology (ASH) Annual Meeting, held on 6-9 December, results from the global, ...

Immunome’s acquired gamma secretase inhibitor, varegacestat, has demonstrated its efficacy and tolerability in a Phase III study, meaning the company will now file for the drug’s approval with the FDA ...

argenx plans to carry out a comprehensive analysis of the trial data after the close out and the database lock. Credit: Wirestock Creators / Shutterstock.com. argenx has announced the discontinuation ...

The trial will enrol 300 chronic low back pain patients with inflammatory degenerative disc disease of less than five years duration. Credit: Anatoliy Cherkas / Shutterstock. Australia-based Mesoblast ...